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Abstract 
Objective: To determine whether there are differences in prostate specific antigen (PSA) at 
diagnosis or changes in PSA between US and European populations of men with and without 
prostate cancer. 
Subjects and methods: Repeated measures of PSA from six clinically and geographically 
diverse patient cohorts: two cohorts of men with PSA-detected prostate cancer, two cohorts 
with clinically-detected prostate cancer and two cohorts of men without prostate cancer. 
Using multilevel models, average PSA at diagnosis and PSA change over time were 
compared between populations. 
Results: Annual percentage PSA change of 4-5% was similar between men without cancer 
and men with PSA-detected cancer.  PSA at diagnosis was 1.7ng/ml lower in a US cohort of 
PSA-detected men (95% CI 1.3-2.0ng/ml), compared to a PSA-detected UK cohort, but there 
was no evidence for a different rate of PSA change between these populations.  
Conclusion: PSA changes over time are similar in UK and US men diagnosed through PSA 
testing and even in men without prostate cancer. Further development of PSA models to 
monitor men on active surveillance should be undertaken in order to take advantage of 
these similarities. We found no evidence that guidelines for using PSA to monitor men 
cannot be passed between US and European studies. 
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1. Introduction 1 
Active surveillance (AS) is increasingly being used as an alternative to immediate radical 2 
intervention for men with localised prostate cancer, at low risk of progressing to life 3 
threatening disease(1-3). As radical treatment comes with a risk of harm(4), there is strong 4 
motivation to intervene in only those men with a high risk of disease progression.  5 
Circulating prostate specific antigen (PSA) has been used as a biochemical measure of 6 
prostate cancer for many years. AS commonly includes regular measurement of PSA, with 7 
increasing values used as a trigger for review. If signs of disease progression are found on 8 
clinical review, there is the opportunity for radical intervention before the opportunity for 9 
cure has passed.  10 
Dynamic measures of PSA, such as PSA doubling time and PSA velocity are used by several 11 
AS studies to alert clinicians to rapidly rising PSA(5). Furthermore, PSA levels increase 12 
naturally with age, and methods are being developed to indicate when increases in PSA are 13 
beyond normal age-related(6-9). However, there is currently no evidence on whether there 14 
is common PSA change in men with localised prostate cancer in different populations. 15 
Although AS studies are beginning worldwide, the larger, more mature cohorts are based in 16 
Europe and North America(10). Differences in the effect of PSA screening have been 17 
suggested between these populations(11, 12), although there are several flaws with this 18 
interpretation(13). Nevertheless, the American Medical Association recommends annual 19 
screening after age 55 in the US(14), while no such recommendations exist in Europe.   20 
This could lead to different populations of men with prostate cancer in the US (e.g. detected 21 
at an earlier stage), who then may or may not have similar PSA kinetics to their European 22 
counterparts. Thus it is unclear whether longitudinal PSA changes may differ in men on AS. 23 
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Monitoring protocols and triggers for clinical review are being devised to suit all men on AS 24 
without requiring recalibration to each new population. It is therefore crucial to investigate 25 
these differences and to adjust PSA protocols if necessary. Further, if PSA change is found to 26 
be similar on average in men with and without prostate cancer then, for a future individual, 27 
it may be possible to separate normal age-related change in PSA from pathologically 28 
influenced changes which are a symptom of more aggressive cancer.  29 
To this end, this article provides comparisons of (i) PSA change in men with and without 30 
prostate cancer; (ii) PSA change in men with prostate cancer who were detected clinically or 31 
through a PSA test; and (iii) PSA change in UK and US men in modern AS studies.32 
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2. Methods 33 
2.1 Study Populations 34 
Data were available from ongoing AS studies based at the Royal Marsden(15) and Johns 35 
Hopkins(16) hospitals. The Royal Marsden data include 492 men and 9243 PSA tests 36 
(obtained between 1999 and 2012) while the Johns Hopkins data comprises 6352 PSA test 37 
results from 994 men (obtained between 1993 and 2012). In most men diagnosis was based 38 
on a raised PSA value and subsequent positive biopsy, so this represents a modern AS 39 
cohort.  40 
The Scandinavian Prostate Cancer study Group 4 (SPCG4) cohort analysed here contains 198 41 
men and 2120 PSA tests(17), and the University of Connecticut Health Centre (UCHC) cohort 42 
consists of 101 men and 775 PSA test results(18, 19). In both cohorts, men were diagnosed 43 
with localised prostate cancer between 1989 and 1993 and represent a population whose 44 
disease was likely detected at a later stage than in the PSA era, in the most part through 45 
clinical presentation with symptoms, or incidentally during treatment for urological 46 
conditions.  47 
Two cohorts of men without prostate cancer were also included to examine differences in 48 
PSA change between men with and without cancer. Data from the Baltimore Longitudinal 49 
Study of Aging (BLSA)(20) contained 5012 PSA measurements from 1032 men without 50 
prostate cancer. A model for PSA change in 1432 men without cancer from the Krimpen 51 
study(21, 22) (a large prospective community-based study in the Netherlands) has appeared 52 
elsewhere(8), and the coefficients from this model are presented here for comparison. 53 
PSA was collected for a variety of reasons among these six cohorts (Table 1), and the 54 
differences between these could lead to biases in modelling these PSAs together. However, 55 
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all were measured on men who were untreated for prostate cancer, i.e. these were `natural’ 56 
observations of PSA in later life in several thousand men. 57 
2.2 Comparing PSA change between men with and without prostate cancer 58 
In each of the five cohorts (Royal Marsden, Johns Hopkins, SPCG4, UCHC and BLSA), we 59 
modelled repeated measures of PSA using a separate multilevel model (with a random 60 
intercept and slope). In each model, we log transformed PSA values to account for the 61 
skewed distribution of PSA. The intercept and slope of these models are presented to 62 
compare the average PSA level at 50 (age was centred at 50 in each model to correspond to 63 
the Krimpen model(22), and because there is no age at diagnosis for Krimpen or BLSA) and 64 
percentage change in PSA value per year from 50-80 (the maximum age in the data) 65 
respectively. These models have previously been applied to the Krimpen study(22), so here 66 
we can compare change in PSA levels between six cohorts: two from men without prostate 67 
cancer (BLSA and Krimpen); two from the clinically detected era of prostate cancer (SPCG4 68 
and UCHC); and two from the modern PSA-detected era of prostate cancer (Royal Marsden 69 
and Johns Hopkins). 70 
2.3 Comparing PSA trends between PSA detected men and clinically detected men with 71 
prostate cancer 72 
Log transformed PSA data from the four prostate cancer cohorts were combined and a 73 
multilevel model was fit to these data, including an interaction term between cohort and 74 
age, so that a comparison of PSA change could be made. This model also included Gleason 75 
score at diagnosis (3+3, 3+4 or 4+3) and its interaction with age, so that we could further 76 
compare whether Gleason score had an association with average PSA level or PSA change. 77 
Time from diagnosis, rather than age, was used as the time-varying covariate to allow for 78 
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interpretation of the intercept as the average estimated PSA value at diagnosis. To correct 79 
for different ages of men in the studies, we controlled for age at diagnosis in the models. 80 
Within subject variation was allowed to be different in each study, to improve model fit, and 81 
this is reported as a measure of the natural variation of PSA levels over time for men in each 82 
cohort. 83 
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3. Results 84 
Table 2 summarises the PSA data in each of the six cohorts. On average, the SPCG4 cohort 85 
has the highest average PSA value at diagnosis (8.9ng/ml) while the UCHC cohort has the 86 
oldest cohort at diagnosis (69.8 years). The Royal Marsden and UCHC cohorts are similar in 87 
terms of diagnostic PSA and follow-up time, but there are many more PSA tests per person 88 
in the more modern Royal Marsden cohort. Johns Hopkins has the lowest average PSA at 89 
diagnosis (5.0ng/ml) and shortest follow-up time (3.5 years), yet has the most men on 90 
surveillance (994) among the cancer cohorts. There was a similar proportion of Gleason 3+3 91 
men in the modern AS cohorts (91% in RMH, 95% in Johns Hopkins), but this was lower in 92 
UCHC (75% 3+3 men) and SPCG4 (67% 3+3 men). 93 
3.1 Comparing PSA change between men with and without prostate cancer 94 
Men on surveillance and men without prostate cancer have similar age-related PSA change 95 
(Table 3). For example, the average PSA change per year is very similar in the Krimpen, BLSA, 96 
Royal Marsden and Johns Hopkins cohorts, with a 4- 5% increase in PSA per year. Men in the 97 
older, clinically detected cohorts have a much steeper rate of change, increasing by 7% and 98 
14% per year in UCHC and SPCG4 respectively. 99 
The left panel of Figure 1 shows a PSA curve for a hypothetical man in each cohort who has 100 
a PSA value of 2ng/ml at age 50. This graph is used to show the similarities of the four 101 
modern cohorts, whether they involve men with or without prostate cancer. However, the 102 
results from the multilevel models suggest that men without cancer have much lower 103 
average PSA values at age 50 – both have an average estimated PSA value below 1ng/ml. In 104 
the right panel of Figure 1, the estimated average PSA level at age 50 is much lower in the 105 
Krimpen and BLSA cohorts. However, since only men with raised PSA levels are biopsied, the 106 
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disease status of men in these cohorts is unclear. The low average PSA value estimate at age 107 
50 for the clinically detected men (SPCG4 and UCHC) is a result of extrapolating below the 108 
ages of men in these two cohorts. 109 
3.2 Comparing PSA trends between men with PSA-detected and clinically detected 110 
prostate cancer 111 
The combined model included 1855 men and 18645 repeated measures of PSA (average 10 112 
per person, range 1 to 54), results are shown in Table 4. The Royal Marsden men with 113 
Gleason score 3+3 provided the largest amount of PSA data and were used as the reference 114 
group. They had mean PSA value at diagnosis of 5.56ng/ml (95% CI 5.21-5.93ng/ml) with a 115 
PSA change of 5.7% per year (95% CI 4.3-7.1%). Both US cohorts had a lower PSA value at 116 
diagnosis than the UK AS study, with PSA level at diagnosis estimated as 3.93ng/ml in Johns 117 
Hopkins (95% CI 3.63, 4.25ng/ml) and 4.24ng/ml in UCHC (95% CI 3.60-5.00ng/ml). 118 
However, there was no strong evidence for a difference in the rate of change of PSA 119 
between UK and US populations, with PSA increasing by 5.7% (95% CI 4.3-7.1%) and 5.9% 120 
(95% CI 4.1-7.8%) in Royal Marsden and Johns Hopkins respectively. Men in the SPCG4, 121 
clinically detected, cohort had a higher PSA value at diagnosis on average (8.54ng/ml, 95% 122 
CI 7.64-9.55) and a higher rate of PSA change per year (17.3%, 95% CI 14.5-20.1%) compared 123 
with the Royal Marsden AS men. 124 
Men with Gleason scores 3+4 (6.26ng/ml, 95% CI 5.73, 6.83ng/ml) and 4+3 (9.67ng/ml, 95% 125 
CI 6.60, 14.17ng/ml) had higher PSA value at diagnosis than Gleason 3+3 men (5.56, 95% CI 126 
5.21, 5.93). There was also evidence that men with Gleason score 4+3 (23.1% increase per 127 
year, 95% CI 10.9, 36.7%) had a higher rate of PSA change compared to Gleason 3+3 men 128 
(5.7% increase per year, 95% CI 4.3, 7.1%). The within subject variation in PSA level was 129 
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higher in the older, clinically detected cohorts, with an average variation of 0.324ng/ml 130 
(95% CI 0.314, 0.335ng/ml) and 0.404ng/ml (95% CI 0.383, 0.426ng/ml) in the SPCG4 and 131 
UCHC cohorts respectively, compared to 0.270ng/ml (95% CI 0.266, 0.274ng/ml) in Royal 132 
Marsden and 0.261ng/ml (0.255, 0.266ng/ml) in the Johns Hopkins cohort. 133 
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4. Discussion 134 
Longitudinal PSA changes over time were similar between men without prostate cancer 135 
(BLSA and Krimpen cohorts) and men with cancer detected by a PSA test (Royal Marsden 136 
and Johns Hopkins cohorts), with PSA values rising by between 4 and 5% per year between 137 
the ages of 50 and 80. However, men without cancer had lower average PSA levels 138 
estimated at 50 years. In clinically detected men, the rate of increase was higher - between 139 
7% (UCHC) and 14% (SPCG4) per year. A more in-depth comparison of the prostate cancer 140 
cohorts suggested that the average PSA level at diagnosis was 1.6ng/ml lower in US 141 
compared to UK populations, and 3ng/ml higher at diagnosis in clinically detected European 142 
men, compared with PSA-detected UK men. We found no strong evidence for PSA change 143 
differences between modern AS men in the US and UK populations. However, clinically 144 
detected men (SPCG4) had an 11.5% per annum higher rate of PSA change, compared with 145 
modern AS men in the UK. The Royal Marsden (Europe-PSA) and UCHC (USA-symptomatic) 146 
are similar in baseline and overall PSA. This suggests that while PSA at diagnosis is likely 147 
lower in the US (perhaps due to repeat PSA testing), PSA change is similar between modern 148 
AS populations.  149 
We also find that men with more aggressive cancer (Gleason score 4+3), have much higher 150 
rates of PSA increase than men with Gleason score 3+3. This suggests PSA may be useful as 151 
a biomarker in more aggressive cancer, while in the majority of lower grade tumours, PSA 152 
change is comparable to men without cancer. The change in PSA in the Gleason 4+3 men is 153 
23% per year (95% CI 11-37%) and there is strong evidence in other studies that higher 154 
Gleason score is associated with increased mortality(23). However, without any clinical 155 
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outcomes such as metastases, no strong conclusions can be made here for the clinical utility 156 
of PSA.  157 
In order to use PSA in AS, a model for "normal" PSA levels is needed, as a comparator for 158 
observed PSA levels in men on AS. From Table 5 it is evident that PSA doubling time, PSA 159 
velocity and absolute level of PSA are commonly used measures for monitoring a man’s PSA 160 
level(5, 24, 25). There is little consensus on which of these to use or what threshold should 161 
be employed for each measure. There remains an absence of clinical or statistical evidence 162 
for their use in active monitoring, and retrospective analyses have found very little 163 
association with clinical outcomes such as metastases or prostate cancer specific 164 
mortality(5, 26-29). Furthermore there are concerns about the various methods of 165 
calculation of PSA doubling time(30, 31) and PSA velocity(32, 33) as well as a great deal of 166 
variation and uncertainty about how many PSA values should be used for calculation(7). PSA 167 
levels increase naturally with age, so that a method is needed to indicate when increases in 168 
PSA are beyond normal age-related change, to avoid reviews being triggered when they are 169 
not necessary. 170 
It has recently been suggested that a single early PSA test (around age 40-55) might be used 171 
to determine aggressive prostate cancer in later life(34). A similar test early in AS may also 172 
be useful in determining the frequency of PSA monitoring during AS. Answering this 173 
question is beyond the scope of the current analysis, and would require AS studies with 174 
enough clinical events (e.g. metastases) to distinguish PSA trends between fatal and non-175 
fatal prostate cancers. Some work on this topic has recently appeared(35), suggesting that 176 
not enough clinical events are currently available to perform such an analysis. 177 
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Strengths of this study include the large amount of data available for model development 178 
and validation, with the combined model using data from 1855 men and 18645 PSA tests. 179 
Our data come from both the US and UK populations and traverse two eras of prostate 180 
cancer detection: the symptomatic presenting man from the early 1990s and the PSA-181 
detected man of the 2000s. The follow-up periods for these men were relatively long, with 182 
3.5, 4.4, 4.7 and 6-year averages for the prostate cancer cohorts. It was also very important 183 
to have Gleason score available for each cohort, so this could be investigated alongside 184 
cohort effects. 185 
One limitation of this work is censoring by treatment in the modern AS cohorts. In both 186 
Royal Marsden and Johns Hopkins, men with rapidly rising PSA are more likely to receive 187 
treatment than men with stable PSA, due to triggers for clinical review which involve 188 
PSA(10, 16, 36), although we did not have any data on whether a man has left AS due to 189 
censoring by treatment, death or end of study. This may explain the differences between 190 
the UCHC and SPCG4 cohorts. For example, in UCHC there may have been more sensitive 191 
PSA criteria for clinical review, such that men with rapidly rising PSA are not included in the 192 
available data, whereas in SPCG4 they are included. Selection bias may have been 193 
introduced by the different populations of men being included in the combined analysis. 194 
Inclusion criteria and triggers to leave surveillance were different between the four cohorts 195 
of men with prostate cancer, and they were diagnosed by different means (PSA tests vs 196 
clinically presenting with symptoms). Men in SPCG4 were randomised as part of an RCT to 197 
follow a conservative management approach, while men in Johns Hopkins, Royal Marsden 198 
and Connecticut all were recruited to active surveillance programs after a diagnosis of 199 
clinically localised prostate cancer. However, the PSA data from these four cohorts come 200 
from men with untreated, clinically localised prostate cancer. From Table 5 it is evident that 201 
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differences in AS eligibility, monitoring and triggers to leave surveillance remain diverse. 202 
Thus, using these large datasets while controlling for study provides best possible 203 
comparison of PSA change between populations.  204 
The evidence provided here, namely that PSA change is similar in contemporary cohorts of 205 
AS with and without localised prostate cancer in both Europe and the US, suggests that 206 
models for PSA change could be developed for use in monitoring studies. For instance, PSA 207 
doubling time and PSA velocity are currently calculated for each man separately and 208 
compared to fixed thresholds (e.g. PSA doubling time < 3 years is used by several 209 
studies(10)). If PSA change is similar between populations, a database of PSA change could 210 
be established, such that comparisons of an individual’s PSA doubling time with other 211 
similar men could be made. These comparisons may be more useful at determining 212 
abnormal PSA doubling time, than comparing with a fixed threshold. Indeed, as more and 213 
more men are entered into AS studies, this collection of data would be continually 214 
strengthened, leading to improved ability to pick out adverse changes in PSA during 215 
monitoring.  216 
National Institute for Health and Care Excellence(37) guidelines suggest monitoring men on 217 
AS using PSA kinetics. Since the large US and Canadian studies drive the thresholds used to 218 
make clinical decisions (e.g. PSA doubling time < 3 years used in a large Toronto study(38) 219 
has been adopted by the largest ongoing AS study, PRIAS(39)), it is important to see 220 
whether clinicians in the UK and Europe should base their PSA kinetic decisions on these 221 
thresholds. We find little evidence for a difference in PSA change during follow-up between 222 
US and UK men, which suggests that using thresholds from the large US and Canadian 223 
studies is appropriate in other populations. 224 
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Table 1: Description of the studies used for analysis of PSA trends 
Cohort RMH JH UCHC SPCG4 BLSA Krimpen 
Circumstances 
of PSA 
collection 
Ongoing 
prospective 
active 
surveillance 
study(36) 
Ongoing 
prospective 
active 
surveillance 
study(16) 
Prospective 
active 
surveillance 
study(19) 
Randomised 
controlled trial of 
watchful waiting 
against radical 
prostatectomy. 
PSA collected on 
men in the WW 
arm of the 
RCT(17) 
Ongoing 
prospective 
study of 
aging and 
PSA(20) 
Prospective 
study of 
aging and 
PSA(21, 22) 
Years of 
diagnosis 
1999-2010 1992-2012 1990-1993 1989-1999 n/a n/a 
Years of PSA 
testing 
1999-2012 1992-2012 1990-2005 1989-2005 1990-2012 1995-2004 
Inclusion 
criteria 
Baseline PSA 
< 15ng/ml; 
Gleason 
score  3+4; 
T2; % 
positive 
biopsy cores 
 50% 
PSA density < 
0.15ng/ml/cm3; 
Gleason score  
3+3; T1c; two or 
less positive 
biopsy cores; 
maximum 
involvement of 
50% per core 
Age<75, 
Baseline 
PSA  < 
10ng/ml; 
Gleason  
6; 
1-2 cores + 
<50% in 
any single 
core 
Age < 75; T0d, 
T1, or T2; 
life expectancy 
> 10 years. 
Age: 20-97, 
no prior 
diagnosis of 
prostate 
cancer. Men 
with a 
diagnosis of 
prostate 
cancer during 
follow-up, 
were 
censored 
Age: 50-78, 
no prior 
diagnosis of 
prostate 
cancer. Men 
with a 
diagnosis of 
prostate 
cancer during 
follow-up, 
were 
censored 
Monitoring 
schedule 
PSA tests 
every 3-4 
months in 
the first 2 
years then 
every 6 
months 
PSA tests every 6 
months 
PSA tests 
every 6 
months. 
If trending 
upward, 
every 3 
months 
 
PSA tests every 6 
months for two 
years and 
annually 
thereafter 
Every 1 to 4 
years 
depending on 
age 
Baseline PSA 
tests and 
subsequent 
follow-up 
tests after an 
average of 
2.1, 4.2 and 
6.5 years 
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Table 2: Descriptive statistics for each cohort 
Study Description Cohort 
size 
PSA 
tests 
Median 
tests per 
individual 
Average 
follow-
up (st. 
dev.) 
Average 
age at 
first PSA 
(st. dev.) 
Average 
first PSA, 
ng/ml 
(st. dev.)  
Gleason 
grade 
(%) 
Krimpen 
(Netherlands) 
Men without 
PCa 
1462 3353 3 4.2 61.1 (6.6) 1.7 (1.8) n/a 
BLSA (USA) Men without 
PCa 
1032 5012 3 13.2 
(10.9) 
52.0 
(16.1) 
1.42 (2.7) n/a 
Royal 
Marsden (UK) 
Men with 
localised PCa 
on AS 
492 9243 19 4.4 (2.6) 65.7 (6.2) 6.90 (3.5) 3+3 
(91%) 
3+4 (8%) 
4+3 (1%) 
Johns Hopkins 
(USA) 
Men with 
localised PCa 
on AS 
994 6352 5 3.5 (2.8) 65.7 (6.1) 4.96 (2.8) 3+3 
(95%) 
3+4 
(5%) 
4+3 (0%) 
SPCG4 
(Sweden) 
Men with 
clinically 
detected 
PCa, on WW 
198 2120 11 6.0 (3.8) 67.2 (5.7) 8.91 (5.1) 3+3 
(67%) 
3+4/4+3 
(33%) 
UCHC (USA) Men with 
clinically 
detected 
PCa, on WW 
101 775 6 4.7 (3.9) 69.8 (4.5) 6.66 (4.4) 3+3 
(75%) 
3+4 
(11%) 
4+3 
(14%) 
AS = active surveillance, PCa = prostate cancer, WW = watchful waiting 
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Table 3: Coefficients from linear multilevel models for log(PSA) change in each of six cohorts 
 Men without prostate 
cancer 
 Men with prostate cancer 
Cohort Krimpen(21) BLSA   Royal Marsden  JH SPCG4 UCHC 
Estimated PSA value 
at age 50 (ng/ml)  
0.73 0.65  2.55 2.08 1.10 1.23 
Percentage change 
in PSA per year in 
age (%) 
4.54 4.14  4.68 4.15 14.0 7.10 
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Table 4: Results from a multilevel model of repeated log(PSA) data, including data from all four prostate 
cancer cohorts 
 Parameter  Category Coefficient 95% confidence 
interval 
  p-value for difference 
between categories 
Average PSA value at 
diagnosis  
Royal 
Marsden 
5.56ng/ml 5.21, 5.93ng/ml p<0.0005 
 Johns 
Hopkins 
3.93ng/ml 3.63, 4.25ng/ml  
  SPCG4 8.54ng/ml 7.64, 9.55ng/ml  
 UCHC 4.24ng/ml 3.60, 5.00ng/ml  
Change in PSA per year  Royal 
Marsden 
5.72% 4.31, 7.14% p<0.0005 
 Johns 
Hopkins 
5.92% 4.05, 7.81%  
  SPCG4 17.31% 14.56, 20.12%  
 UCHC 5.68% 1.92, 9.58%  
Average PSA value at 
diagnosis by Gleason score 
3+3 5.56ng/ml 5.21, 5.93ng/ml p<0.0005 
 3+4 6.26ng/ml 5.73, 6.83ng/ml  
  4+3 9.67ng/ml 6.60, 14.17ng/ml  
Change in PSA per year by 
Gleason score 
3+3 5.72% 4.31, 7.14% p=0.0042 
  3+4 7.53% 5.31, 9.81%  
  4+3 23.11% 10.85, 36.72%  
Average increase in PSA per 
year of age at diagnosis 
 1.53% 0.96, 2.11%  
PSA residual standard 
deviation by study 
Royal 
Marsden 
0.270ng/ml 0.266, 0.274 ng/ml p<0.0005 
 Johns 
Hopkins 
0.261ng/ml 0.255, 0.266 ng/ml  
 SPCG4 0.324ng/ml 0.314, 0.335 ng/ml  
 UCHC 0.404ng/ml 0.383, 0.426 ng/ml  
 
 
 Page 26 of 27 
 
Table 5: Description of the use of PSA for eligibility, monitoring and triggering clinical review in large AS 
studies 
Setting PSA eligibility PSA monitoring PSA trigger for 
clinical review 
Sample size 
(years 
recruited) 
Memorial Sloan 
Kettering Cancer 
Centre, New York, 
USA(41) 
<10 every 6 mo. PSA  10ng/ml 238 (1993-
2009) 
University of Miami, 
USA(42) 
10 every 3-4 mo. for 2 
yrs, then every 6 mo.  
No defined PSA 
trigger 
276 (1994-
2011) 
University of Toronto, 
Canada(38) 
10 2000 - 
 
15 1995-1999 
every 3 mo. for 2 yrs, 
then every 6 mo. for 
stable patients 
 
PSADT < 3 yrs 450 (1995-
2010) 
ERSPC, Gothenburg, 
Sweden(43) 
<10 (low risk gp.) 
 
 
 
< 20 (inter risk gp.) 
every 3-6 mo. “Established PSA 
progression” 
439 (1995-
2010) 
UC, San Francisco, 
USA(44) 
within CAPRA score every 3 mo. PSADT 2yrs 466 (1995-
2010) 
Johns Hopkins 
University, USA(16) 
PSA density < 
0.15ng/ml/cc 
every 6 mo. PSA density  
0.15/ml/cc 
769 (1995-
2011) 
Royal Marsden NHS 
Trust, UK(45) 
<15 every 3 mo. in 1st yr, 
every 4 mo. in 2nd yr, 
every 6 mo. after 2 
yrs 
PSAv>1ng/ml/yr, 471 (2002-
2011) 
PRIAS (International), 
Rotterdam based, 
Holland(39) 
10 ; 
PSAD<0.2ng/ml/cc 
every 3 mo. for 2 yrs, 
then every 6 mo. 
PSADT < 3yrs 2494 (2006-
2012) 
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Figure 1: PSA change in the six cohorts: change for a man with an initial PSA at age 50 of 2ng/ml 
(left); change using actual estimated PSA at age 50 (right) 
 
